Micafungin (Mycamine) for fungal infections

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1211, 2005, Pages 51-52

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN; CYCLOSPORIN A; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; CYCLOPEPTIDE; LIPOPROTEIN;

ANAPHYLAXIS; AREA UNDER THE CURVE; CANDIDIASIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENDOSCOPY; ENZYME DEFECT; ESOPHAGUS CANDIDIASIS; FACE EDEMA; FEVER; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; INJECTION SITE PHLEBITIS; LEUKOPENIA; LIVER DISEASE; MYCOSIS; NAUSEA; NONHUMAN; PRURITUS; RASH; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; DRUG INTERACTION; ESOPHAGUS DISEASE; INTRAVENOUS DRUG ADMINISTRATION;

ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; ESOPHAGEAL DISEASES; HUMANS; INJECTIONS, INTRAVENOUS; LIPOPROTEINS; MYCOSES; PEPTIDES, CYCLIC;

EID: 21744435940     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther 2001; 43:58.
2. AH Groll et al. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343.
3. DW Denning. Echinocandin antifungal drugs. Lancet 2003; 362:1142.
4. PL Carver. Micafungin. Ann Pharmacother 2004; 38:1707.
5. N de Wet et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842.
6. N De Wet et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899.
7. JH van Burik et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407.
8. S Kohno et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36:372.
9. S Shimoeda et al. Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull 2005; 28:477.
10. KA Marr et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis. 2004; 6:110.
11. C Sanz-Rodriguez et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34:13.